News from MEDIACC.


Long-awaited – the "Rules of Procedure for the Further Development of the List of Aids and Devices" is available as of today


Medical aids – ranging from the bandage to the walking aid to cochlear implants – ensure the best possible and safe care for patients. In view of the innovations – for example, in the field of digital medical care with apps, the constant increase in knowledge through clinical studies and research and the increased quality requirements, mainly due to MDR – a continuous adaptation of the list of aids and nursing aids is indispensable. The new procedural rules describe how existing product groups can be continued in the list of medical aids and how manufacturers can introduce their products to the list of medical aids in order to enable reimbursement by health insurance funds. The further development and innovation of novel aids form the basis of high-quality care. The Rules of Procedure regulate the course of action for including new product groups and types in the list of aids, such as new types of hearing aids and app-controlled administrations.

The aim is to enable manufacturers to establish a regulated, structured and comprehensible process to ensure that the list of aids is always up to date. The legally insured persons, i.e. about 90% of the Germans, thus have fast, up-to-date and secure access to the latest medical developments and medical products. Germany will once again set high quality standards and remain an attractive market for medical device manufacturers. We look forward to taking you and your medical devices on the way to the medical aids directory in accordance with the new procedural rules.

1Rules of Procedure of the GKV-Spitzenverband according to § 139 paragraph 7 SGB V

Food supplements and the EU market – a scary story


A buzz about new super food that does wonders to the immune system or is recommended as the miracle detox product keeps haunting the media. Like ghosts, these claims tend to lack evidence. Clever and creative marketing strategies to boost sales? Or could there be solid scientific evidence about food that is good for our health?

Lots of these products are available in form of food supplements. What is that?

According to the food supplements Directive (Directive 2002/46/EC), food supplements are defined as foodstuffs that are meant to supplement the normal diet. Thus, they are concentrated sources of nutrients or other substances with a nutritional or physiological effect, alone or in combination, marketed in dose form, namely capsules, pastilles, tablets, pills and other similar forms, sachets of powder, ampoules of liquids, drop dispensing bottles and others, designed to be taken in measured small unit quantities. The respective nutrients can be vitamins, minerals, herbal extracts and other ingredients.

These products are made according to the manufacturing standards, but that does not necessarily guarantee their effectiveness or even safety. So how can one be sure to buy a product that is both safe as well as effective?

A lot of food and food supplements available in the EU bear nutrition claims and/or health claims. A nutrition claim states that the product contains certain nutritional properties, such as “high protein”, “fat-free” or “source of omega-3 fatty acids”. A health claim is any statement on labels about a relationship between the product and health, pointing to possible health benefits resulting from consuming that particular product.

So, who decides who can get a claim and what is needed in order to receive one?

The area of health claims in Europe was unregulated until the end of 2006 when Regulation (EC) No 1924/2006 was published. Since then, claims about food and food supplements cannot be made unless they are authorised by the European Food Safety Authority (EFSA) and listed on a register. Any misleading by false claims without using scientific evidence will lead to serious legal consequences. This not only protects consumers but also promotes innovation and ensures fair competition. The strength of scientific evidence needed in the EU to substantiate a health claim is described as “generally accepted scientific evidence of beneficial physiological effect in humans”. The EFSA decides whether the evidence is substantiated or not.

The next question appears logically: “How is this evidence created?”

Endorsed by laws and regulations starting with the ICH-GCP, formulating the right questions and using sound scientific methods used in order to validate pertinence of a hypothetical claim by producing high quality data. Once the data have been produced and evaluated, usually by conducting a prospective, double-blind, controlled clinical study, an application to EFSA for a specific claim can be made, which will then take time to evaluate the quality and the relevance of the data produced. If the application is successful, the tested product will receive the claim and the manufacturer will have the right to have this information visible on its package. Thus, the consumers do not have to fear any more false marketing tricks, at least in the EU.

Fed up with poltergeists as well?

The MEDIACC crew can help. We like straight forward procedures and support manufactures with integrity and liability, with EU bureaucratic entanglements posing no threat to us. We are prepared! Challenge us and introduce us to your product like others on the market did.

Prescription for Medical Apps?


Imagine you live in the country, your child is ill and the nearest doctor is 20 kilometres away. You have an appointment for a check-up and a whining child in the child seat. Wouldn't it be ideal if your doctor could simply monitor the healing process of your child online using an app and intervene if necessary? This may not be as far away in the future as it might sound.

The new German law of the Federal Ministry of Health,  "Digital Care Act (DVO)",  will in future provide reimbursement of health apps by the health insurance companies. However, it is not yet clear when this will come into force.

On behalf of the German Federal Ministry of Health, the Bertelsmann Foundation is currently developing a quality criteria catalogue for the evaluation of health apps, which will  serve as a quality guideline for the prescription, reimbursement and use of health apps.

This catalogue of criteria is still in progress and is not expected to be published until the end of 2019. Only then will health insurance companies have concrete criteria for the reimbursement of health apps.

Through cooperation agreements between companies and health insurance funds, individual health apps, such as  the ones for tinnitus, mental health or Parkinson's disease, are already being reimbursed.

Health apps serving primarily for the prevention of a disease are already being reimbursed. These are tested by the Central Testing Laboratory for Prevention. Currently there are already 176 prevention apps, which are covered up to 100% by the health insurance companies. This number is continually increasing.

17 September 2019 – World Patient Safety Day: The Safety of Our Patients is Our Priority!


Today is the first World Patient Safety Day worldwide. In order to protect the safety and the best interests of patients in clinical studies, we implement the highest ethical standards and the appropriate regulations in all our studies. This is how we gain the trust of our customers and patients, even when conducting clinical studies with children. Recently, MEDIACC submitted a comprehensive ethical application for a study with an innovative medical device with professional athletes. By carefully choosing the endpoints and intensively training the study centres we can make sure that the study conduct will be performed according to the highest safety standards. 


§ 23b of the Medical Devices Act (MPG) and Medical Device Regulation (MDR)


According to § 23b of the Medical Devices Act (MPG), there is an exception to the requirements of a clinical trial of a medical device (according to §§ 20 to 23a), as long as the corresponding medical device may carry the CE marking and a clinical study is conducted according to the intended purpose of the medical device without additional invasive or other stressful examinations. These studies can then be carried out, for example, in accordance with the medical professional code of conduct for physicians.
In such clinical studies, the product is tested according to the purpose defined by the manufacturer. In the literature, "invasive" means that an examination is carried out specifically for the purpose of the study, e.g. taking blood. Whether a clinical examination is burdensome must be weighed and assessed in each individual case on the basis of various factors and measures that have already been evaluated as such.
Clinical studies according to §23b MPG are not explicitly regulated in MDR 2017/745, which also applies to clinical studies for medical devices. In Germany, these studies will continue to be regulated under national law in the future. At present, there are no new regulations at the national level. (Information from a Notified Body in Germany, September 2019)
Such studies, which may include post-market clinical follow-up (PMCF, Annex XIV) or post-market surveillance (PMS, Article 83) under the above conditions, shall in principle be designed, planned and conducted in strict compliance with good clinical (ICH-GCP) and scientific practice, in accordance with the professional code of conduct for physicians and other applicable laws, regulations and standards.  
However, "incidents" in such a study must be reported by the manufacturer, i.e. the sponsor of the study, to the authority from January 2020 on a "Manufacturer Incident Report for Serious Incidents and Incidents". This also applies to studies that have already begun. 
This allows the effect, benefit, side effects and safety to be demonstrated and proven.


We moved!

Since its foundation in 2013, MEDIACC has been continuously growing.  During our successful work on preclinical and clinical studies, including observational studies and the reimbursement of medical apps, we were able to welcome new employees and thus slowly exceeded our old office capacity. We, furthermore, expanded our sphere of activity. As of August 26, 2019, our base is located at

Bundesallee 32,

10717 Berlin

– very close to our old location, right in the middle between the underground stations Berliner Straße and Güntzelstraße.

Immediately on the first day after the move, MEDIACC resumed its work. Our service for you in the new environment will not only remain at the same superior level, but will even improve from now on! Having been committed to excellence for many years, MEDIACC will continue to assist you with all questions and problems related to the ever-growing healthcare market.

We look forward to welcoming you at our new place of action!




The European Medical Device Regulation (MDR 2017/745)

MEDIACC is well prepared for the application of the European Medical Device Regulation (MDR 2017/745) on Clinical Studies.

Time flies for manufacturer of medical devices and developers of medical apps. The EU MDR 2017/745 will be applicable on May 26th 2020. Transitional arrangements are put into place by the Notified Bodies. However, for medical devices requiring Clinical Studies, the MDR is binding in case last patient / last visit is not finished by this date.

MEDIACC’s employees now received the certificate on Clinical Evaluation and Clinical Studies according to EU MDR 2017/745 by Germany’s first and only designated Notified Body for EU MDR. As certified partner on the side of our clients, we make sure to keep gold standards such as the Declaration of Helsinki and  ISO 14155:2011 as well as implement necessary changes as mandated by the new regulation to protect patients’ rights and safety and increase medical device effectiveness in the EU market.

An interesting feature of the Medical Device Regulation is that words such as “Safety”, “Clinical Data”, “Clinical Evaluation” and “Post Marketing Surveillance” are at least seven time more often used than in the Medical Device Directive (MDD 93/42/EEC).



Clinical evaluation of international paediatric real-world-data

Data of 31 patients have been used in an international paediatric clinical evaluation for an innovative assistive medical device to show improved clinical outcome (94% of users) when used in addition to standard therapy. Thanks to the proficient cooperation with our university partners and clinical experts, quality of data was first-rate due to meticulous attention to details and expert knowledge. In short time, results could be published in a highly ranked free full-text peer-review journal to change therapeutic perspective for people with physical disabilities.


Our special thanks go to our patients and their families who gave their consent for their data being used – thank you!



Best in class

The Berlin University Alliance, including the Charité, has won the Excellence Initiative for top university research. The German government will provide an additional 200 million Euros over the next few years to support excellent university facilities for outstanding research projects. 
We congratulate all stakeholders and our cooperation partners on this great success. The funding will enable to further develop the cooperating university locations and Berlin as a top international science location.